A Multi-arm Phase IIB Randomised, Double Blind Placebo-controlled Clinical Trial Comparing the Efficacy of Three Neuroprotective Drugs in Secondary Progressive Multiple Sclerosis.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Amiloride (Primary) ; Ibudilast (Primary) ; Riluzole (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms MS-SMART
- 26 Mar 2020 Biomarkers information updated
- 13 Nov 2013 Planned initiation date changed from 1 Oct 2013 to 1 Dec 2013 as reported by ISRCTN: Current Controlled Trials record.
- 13 Nov 2013 Status changed from not yet recruiting to recruiting as reported by ISRCTN: Current Controlled Trials record.